Synthetic analog · 8 amino acids · 1,096.3 Da

Lanreotide studies and research data

PepBank has 110 lanreotide studies with results. 109 of them gave lanreotide, with 585 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 585 results and 908 papers. Newer studies from Europe PMC

Results in people

532

91% of 585 results

Results in animals

2% of 585 results

Results in lab cells

7% of 585 results

From computer models

0% of 585 results

The molecule

Lanreotide identity

Identifiers, parent molecule, targets and development stage, from curated data.

Lanreotide is a cyclic eight-residue somatostatin analog. The US prolonged-release product treats acromegaly, selected neuroendocrine tumors, and carcinoid syndrome.

Kind: Synthetic analog · 8 residues
Identifiers: ChEMBLCHEMBL1201185 (opens in a new tab)PubChem CID6918011 (opens in a new tab)UNII0G3DE8943Y (opens in a new tab)DrugBankDB06791 (opens in a new tab)CAS108736-35-2
Parent: Analog of SomatostatinThe label identifies lanreotide as a cyclic octapeptide analog of natural somatostatin. UniProt P61278 identifies the human somatostatin precursor. No contiguous parent sequence positions are assigned.
Development: Approved in the US and EU (Somatuline Depot)An approved medicinal product exists. Availability and other indications can differ. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Somatostatin receptors	Agonist	Official prescribing information, mechanism of actionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

8 amino acids · 2 modifications · 1 disulfide bond

H-

CYKVCT

Parent: Somatostatin

No sequence is listed for the parent, so no alignment is shown.The label identifies lanreotide as a cyclic octapeptide analog of natural somatostatin. UniProt P61278 identifies the human somatostatin precursor. No contiguous parent sequence positions are assigned.

Properties

From identity sources

Formula: C₅₄H₆₉N₁₁O₁₀S₂
Molecular weight: 1,096.34 g/mol
Monoisotopic mass: 1,095.467 Da

GSRS UNII 0G3DE8943Y(opens in a new tab)retrieved 2026-10-27
PubChem CID 6918011(opens in a new tab)retrieved 2026-10-27
Curated Somatuline Depot US label(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): Not calculated
Extinction coefficient, 280 nm (Cys reduced): 6,990 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Extinction coefficient, 280 nm (all Cys as cystines): 7,115 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: Not calculated
Aliphatic index: Not calculated
Boman index: Not calculated
Hydrophobic moment (μH): Not calculated

1 non-canonical residue (X) is not included in calculated values.
D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Composition

Hydrophobic13% (1)V
Aromatic25% (2)W Y
Positive13% (1)K
Polar13% (1)T
Special25% (2)C
Non-canonical13% (1)X

8 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile0 · 0%

L Leu0 · 0%

M Met0 · 0%

V Val1 · 13%

F Phe0 · 0%

W Trp1 · 13%

Y Tyr1 · 13%

H His0 · 0%

K Lys1 · 13%

R Arg0 · 0%

D Asp0 · 0%

E Glu0 · 0%

N Asn0 · 0%

Q Gln0 · 0%

S Ser0 · 0%

T Thr1 · 13%

C Cys2 · 25%

G Gly0 · 0%

P Pro0 · 0%

X Xaa1 · 13%

3D structure

PredictedAlphaFold DB · P61278

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 6918011(opens in a new tab)

C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O

Results by area

Lanreotide results by year and outcome

Counts are exact and come from studies that gave the peptide.

Lanreotide has 908 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

Studies by year

110 of 908 studies have results (12%), published 1993 to 2026. Top row: every study. Bottom row: studies with results about Lanreotide, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies908 in all, 1993 to 2026

Studies with results110 in all, 1993 to 2026

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Lanreotide studies on growth hormone and growth

118 results · people 109 · animals 1 · lab 8

Top 5 of 118 results

In Chinese patients with acromegaly, autogel was noninferior to prolonged-release lanreotide for IGF-1 SDS in the ITT analysis.BMC endocrine disorders, 2020
In rats with aortic allografts, lanreotide reduced locally produced insulin-like growth factor 1.FASEB journal, 1993
In cells from a human bronchial carcinoid, lanreotide reduced GHRH secretion.The Journal of clinical endocrinology and metabolism, 2005
In acromegaly with large pituitary tumors, lanreotide pretreatment increased cure at 4 months after surgery compared with direct surgery.European journal of endocrinology, 2010
In acromegaly, significantly more patients achieved surgical cure with preoperative lanreotide: 11 of 24 versus five of 25 with direct surgery.The Journal of international medical research, 2012

Lanreotide studies on cancer

121 results · people 103 · animals 2 · lab 16

Top 5 of 121 results

In patients with enteropancreatic NETs, lanreotide prolonged time without disease progression compared with placebo.The New England journal of medicine, 2014
In advanced liver cancer, five lanreotide-treated patients (24%) had blood AFP decreases of at least 30%.International journal of oncology, 2000
In NFPMA patients, lanreotide did not significantly change tumor diameter compared with placebo.The Lancet regional health. Europe, 2024
In carcinoid syndrome, lanreotide and octreotide reduced urinary 5HIAA equally.Cancer, 2000
In carcinoid syndrome, flushes improved or disappeared in 53.8% on lanreotide versus 68% on octreotide.Cancer, 2000

Lanreotide studies on side effects

95 results · people 95 · animals 0 · lab 0

Top 5 of 95 results

In acromegaly with large pituitary tumors, surgical complications were similar after lanreotide pretreatment and direct surgery.European journal of endocrinology, 2010
In patients with enteropancreatic NETs, treatment-related diarrhea occurred in 26% with lanreotide versus 9% with placebo.The New England journal of medicine, 2014
In adults with postoperative dumping syndrome, adverse event counts did not differ significantly between lanreotide and placebo.United European gastroenterology journal, 2019
In Chinese patients with acromegaly, safety profiles were similar with both lanreotide formulations.BMC endocrine disorders, 2020
Injection site discomfort occurred more often with lanreotide than with standard care.JAMA, 2018

Lanreotide studies on stomach and gut

49 results · people 49 · animals 0 · lab 0

Top 5 of 49 results

Lanreotide reduced days needing rescue octreotide compared with placebo.Endocrine practice, 2016
In adults with postoperative dumping syndrome, total symptom scores fell versus baseline after lanreotide but not after placebo.United European gastroenterology journal, 2019
After pancreatic surgery, 24-hour pancreatic output did not decrease significantly with lanreotide compared with placebo.Digestive and liver disease, 2002
In malignant bowel obstruction, lanreotide did not significantly improve diary-based response versus placebo.Journal of clinical oncology, 2012
In high-output fistula or enterostomy patients, 9/20 responded with added lanreotide versus 2/20 with standard treatment alone.Alimentary pharmacology & therapeutics, 2024

Lanreotide studies on blood levels and clearance

29 results · people 29 · animals 0 · lab 0

Top 3 of 29 results

In healthy people, lanreotide Autogel absorption rate did not depend on dose from 60 to 120 mg.Clinical pharmacokinetics, 2009
In acromegaly patients, minimum lanreotide concentrations increased proportionally with dose after one administration.Clinical endocrinology, 2005
In healthy subjects, lanreotide infusion and bolus produced equivalent overall drug exposure.Clinical pharmacology and therapeutics, 2004

Lanreotide studies on blood sugar

16 results · people 16 · animals 0 · lab 0

Top 5 of 16 results

HbA1c did not significantly change from baseline during lanreotide treatment in the overall population.Clinical endocrinology, 2017
In healthy men, insulin decreased only 2 h after lanreotide injection compared with the control day.British journal of clinical pharmacology, 1994
Mean fasting glucose did not significantly change from baseline during lanreotide treatment in the overall population.Clinical endocrinology, 2017
In healthy men, glucagon did not change after lanreotide injection compared with the control day.British journal of clinical pharmacology, 1994
In acromegaly patients with diabetes, HbA1c decreased during lanreotide treatment compared with baseline.Clinical endocrinology, 2017

Lanreotide studies on daily life and fitness

16 results · people 16 · animals 0 · lab 0

Top 5 of 16 results

Quality of life did not change significantly with lanreotide compared with standard care.JAMA, 2018
In patients with hormone-refractory prostate cancer, performance status improved in 40% during lanreotide treatment.Cancer chemotherapy and pharmacology, 1995
In functional midgut NET patients receiving lanreotide, 87.5% had a symptomatic response.Journal of neuroendocrinology, 2022
In carcinoid syndrome, 68% preferred lanreotide over octreotide, largely because of simpler administration.Cancer, 2000
In NET patients with carcinoid syndrome, lanreotide increased quality-of-life response versus placebo.Patient related outcome measures, 2019

Lanreotide studies on liver

16 results · people 16 · animals 0 · lab 0

Top 5 of 16 results

In patients with polycystic liver, liver volume decreased with lanreotide and increased with placebo.Gastroenterology, 2009
In patients with ADPKD and polycystic liver disease, lanreotide reduced liver volume growth by 5.91% versus standard care.Gastroenterology, 2019
In patients with ADPKD, lanreotide reduced combined liver and kidney volume growth by 7.18% versus standard care.Gastroenterology, 2019
In ADPKD patients with PLD, several serum bile acids decreased with lanreotide but remained stable without treatment.European journal of clinical investigation, 2024
In ADPKD with polycystic liver disease, liver volume fell 1.99% from baseline with lanreotide and rose 3.92% in controls at 120 weeks.Gastroenterology, 2019

Lanreotide studies on eyes

14 results · people 14 · animals 0 · lab 0

Top 5 of 14 results

In active Graves' eye disease, lanreotide did not significantly improve Clinical Activity Score versus placebo.Journal of endocrinological investigation, 2006
In patients with CNV, the fluorescent area remained stable during lanreotide treatment.Retina, 2003
In patients with CNV, vision remained stable during six months of lanreotide treatment.Retina, 2003
In active Graves' eye disease, eye protrusion did not differ significantly between lanreotide and placebo.Journal of endocrinological investigation, 2006
In patients with CNV, fluorescence intensity decreased during lanreotide treatment, but the difference from baseline was not significant.Retina, 2003

Lanreotide studies on hormones

14 results · people 14 · animals 0 · lab 0

Top 5 of 14 results

In patients with TSH-secreting adenomas, lanreotide reduced TSH to the same extent as octreotide.Clinical endocrinology, 1994
In active acromegaly, symptoms decreased significantly in most patients during lanreotide treatment.Clinical endocrinology, 2008
In patients, measured chromogranin A decreases during lanreotide treatment followed an inhibitory model.The AAPS journal, 2016
In Japanese TSHoma patients, thyroid hormone markers decreased during lanreotide treatment, and normal thyroid status persisted until final assessment.Endocrine journal, 2021
In healthy men, lanreotide reduced plasma TSH from 2 h through day 4.British journal of clinical pharmacology, 1994

Lanreotide studies on survival and serious illness

14 results · people 14 · animals 0 · lab 0

Top 5 of 14 results

In patients with enteropancreatic NETs, overall survival did not differ significantly between lanreotide and placebo.The New England journal of medicine, 2014
In acromegaly with large pituitary tumors, hospital stays were similar after lanreotide pretreatment and direct surgery.European journal of endocrinology, 2010
No Japanese NET patient died from an adverse event during lanreotide treatment.Asia-Pacific journal of clinical oncology, 2021
In SCLC patients, lanreotide did not significantly prolong overall survival versus observation.Lung cancer, 2019
Median survival was not reached with lanreotide and was 41.9 months with placebo.European journal of cancer, 2022

Lanreotide studies on heart and blood vessels

13 results · people 11 · animals 2 · lab 0

Top 5 of 13 results

In healthy subjects, lanreotide infusion suppressed food-stimulated intestinal artery blood flow more persistently than bolus.Clinical pharmacology and therapeutics, 2004
In cirrhosis, lanreotide reduced baseline portal pressure less than propranolol.Alimentary pharmacology & therapeutics, 2003
In healthy men, lanreotide reduced the meal-induced heart rate increase compared with placebo.Hepatology, 1998
In healthy men, lanreotide reduced the meal-induced fall in diastolic blood pressure compared with placebo.Hepatology, 1998
In cirrhosis, lanreotide reduced the meal-related rise in portal blood flow more than placebo.Digestion, 2002

Lanreotide studies on kidneys and bladder

10 results · people 10 · animals 0 · lab 0

Top 3 of 10 results

Lanreotide did not significantly change annual kidney function decline compared with standard care.JAMA, 2018
In adults with ADPKD, lanreotide did not improve measured kidney filtration versus placebo.Kidney international, 2026
In healthy men, lanreotide did not change renal artery resistance index compared with placebo.Hepatology, 1998

Lanreotide studies on overall treatment results

9 results · people 9 · animals 0 · lab 0

Top 5 of 9 results

In acromegaly, excessive sweating significantly improved during lanreotide treatment.Journal of endocrinological investigation, 2009
In NET patients with carcinoid syndrome, lanreotide increased diarrhea improvement responses versus placebo.Patient related outcome measures, 2019
In acromegaly, abnormal tingling sensations significantly improved during lanreotide treatment.Journal of endocrinological investigation, 2009
In Chinese patients with acromegaly, symptom prevalence decreased from baseline with both lanreotide formulations.BMC endocrine disorders, 2020
In acromegaly patients, lanreotide Autogel controlled symptoms better than lanreotide microparticles.Clinical endocrinology, 2006

Lanreotide studies on use, access and costs

8 results · people 8 · animals 0 · lab 0

Top 5 of 8 results

In patients with acromegaly, fourteen of fifteen met all criteria for successful unsupervised lanreotide administration.Clinical endocrinology, 2008
In NFPMA patients, 13 (59%) completed lanreotide treatment versus 19 (86%) with placebo.The Lancet regional health. Europe, 2024
After both treatments, 47% in the octLAR-first arm and 42% in the lanreotide-first arm reported no preference.JCO oncology practice, 2022
In acromegaly, four patients preferred lanreotide after the study.Clinical endocrinology, 2008
In patients with acromegaly, all home-injection patients or partners qualified to give lanreotide injections.Clinical endocrinology, 2008

Lanreotide studies on pain

5 results · people 5 · animals 0 · lab 0

5 results

In patients with hormone-refractory prostate cancer, bone pain improved in 35% during lanreotide treatment.Cancer chemotherapy and pharmacology, 1995
In necrotizing acute pancreatitis patients given lanreotide, one patient developed pain after refeeding.Pancreatology, 2004
In acromegaly, spinal joint pain significantly improved during lanreotide treatment.Journal of endocrinological investigation, 2009
In patients with NETs, injection pain did not differ significantly between lanreotide and octLAR.JCO oncology practice, 2022
In advanced liver cancer, pain markedly improved in one additional lanreotide-treated patient (5%).International journal of oncology, 2000

Lanreotide studies on metabolism and nutrition

4 results · people 4 · animals 0 · lab 0

Top 3 of 4 results

In healthy men, low-dose lanreotide reduced urea nitrogen synthesis during amino acid infusion compared with saline.Clinical nutrition, 1994
In healthy men, high-dose lanreotide reduced urea nitrogen synthesis during amino acid infusion compared with saline.Clinical nutrition, 1994
In healthy men, low-dose lanreotide increased peak alpha-amino nitrogen compared with placebo.Clinical nutrition, 1994

Lanreotide studies on skin, hair and wounds

3 results · people 3 · animals 0 · lab 0

3 results

After breast cancer surgery, lanreotide did not significantly reduce lymph fluid volume versus placebo.European journal of surgical oncology, 2012
After breast cancer surgery, lanreotide did not significantly change the secondary outcomes versus placebo.European journal of surgical oncology, 2012
In a subgroup having axillary dissection alone, lanreotide reduced lymph fluid volume versus placebo.European journal of surgical oncology, 2012

Lanreotide studies on receptors and cell signals

25 results · people 2 · animals 4 · lab 19

Top 5 of 25 results

In acromegaly patients, AIP staining was stronger after lanreotide pretreatment than with surgery only.The Journal of clinical endocrinology and metabolism, 2012
In rats under anesthesia, lanreotide reduced sympathetic activity with increasing doses, and an sst2 antagonist blocked this effect.Hypertension, 2008
In cells from human thyroid tumors, calcitonin secretion responses to lanreotide differed between groups.The Journal of clinical endocrinology and metabolism, 2006
In lab tests, lanreotide stimulated receptor internalization, with receptors and ECE-1 together in endosomes and the Golgi.The Journal of biological chemistry, 2013
In lab tests with rat gastric cells, lanreotide inhibited histamine release at a reported inhibitory concentration of 2.2 nM.Regulatory peptides, 2007

Lanreotide studies on surgery and procedures

2 results · people 2 · animals 0 · lab 0

2 results

After preoperative lanreotide, eight patients developed a clinically relevant pancreatic fistula or abdominal abscess.HPB, 2022
After preoperative lanreotide, 12 patients had a biochemical leak.HPB, 2022

Lanreotide studies on weight and appetite

2 results · people 2 · animals 0 · lab 0

2 results

In advanced liver cancer, five lanreotide-treated patients (24%) gained weight.International journal of oncology, 2000
In advanced biliary cancer, two patients with stable disease gained weight during lanreotide treatment.Scandinavian journal of gastroenterology, 2002

Lanreotide studies on cholesterol and blood fats

1 result · people 1 · animals 0 · lab 0

1 result

Lipid profile changes during lanreotide treatment were not considered clinically meaningful compared with baseline.Clinical endocrinology, 2017

Lanreotide studies on immune system and inflammation

1 result · people 0 · animals 1 · lab 0

1 result

In rats with aortic allografts, lanreotide did not significantly reduce other inflammatory mediators.FASEB journal, 1993

Trials and papers

Lanreotide trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

85 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (25 of 85)

25 of 85 trials

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

201020202030

Ph 4
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
NCT00145405
Sept 2002 to Dec 2004
Ph 4
ATG1line
NCT00627796
Jan 2003 to Dec 2007
Ph 4
Somatuline Autogel: Acromegaly Self/Partner Injection Study
NCT00149188
Feb 2004 to 24 Aug 2005
Ph 4
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
NCT00216398
Jun 2004 to 22 Jun 2006
Ph 3
CLARINET
NCT00353496
Jun 2006 to Apr 2013
Ph 3
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT00383708
Oct 2006 to Oct 2008
Ph 4
Treatment of the Dumping Syndrome With Lanreotide Autogel®
NCT00543179
Start Oct 2007
Ph 3
PRIMARYS
NCT00690898
May 2008 to Feb 2012
Ph 4
SAPHE
NCT00681187
Jun 2008 to Aug 2010
Ph 4
LEAD
NCT00701363
Oct 2008 to May 2013

Browse all 85 matching trials in the list below

25 trials · 5 ongoing · 16 completed · 2 stopped early · 12 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT03289741

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Memorial Sloan Kettering Cancer Centern = 5119 Sept 2017 to 10 Apr 2023

Neuroendocrine Tumors

Trial page ClinicalTrials.govUpdated 9 May 2025

RecruitingPhase 4NCT05701241

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

University Hospital, Antwerpn = 27028 Jun 2023 to est. Apr 2034

Gastroenteropancreatic Neuroendocrine Tumor

Trial page ClinicalTrials.govUpdated 14 Jun 2024

CompletedPhase 4NCT01070758

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Sheba Medical Centern = 3Feb 2010 to Feb 2015

Congenital Hyperinsulinism

Trial page ClinicalTrials.govUpdated 18 Apr 2024

TerminatedPhase 4Results postedNCT01861717

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Saint John's Cancer Instituten = 4May 2013 to Jan 2016

Acromegaly

Trial page ClinicalTrials.govUpdated 30 Sept 2021

CompletedPhase 4Results postedNCT00681187

Somatuline Autogel Preference and Health Economy Study

Ipsenn = 26Jun 2008 to Aug 2010

Neuroendocrine Tumour With Carcinoid Symptoms

Trial page ClinicalTrials.govUpdated 22 Nov 2019

CompletedPhase 4NCT00216398

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Ipsenn = 8Jun 2004 to 22 Jun 2006

Acromegaly

Trial page ClinicalTrials.govUpdated 16 Aug 2019

CompletedPhase 4NCT00149188

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Ipsenn = 30Feb 2004 to 24 Aug 2005

Acromegaly

Trial page ClinicalTrials.govUpdated 5 Aug 2019

CompletedPhase 4Results postedNCT02075606

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

Ipsenn = 50May 2014 to Jun 2017

NeuroEndocrine Tumours

Trial page ClinicalTrials.govUpdated 7 Jun 2019

Status unknownPhase 4NCT03083210

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Samsung Medical Centern = 285 Jul 2017 to est. Feb 2020

Neuroendocrine Tumors

Trial page ClinicalTrials.govUpdated 20 May 2019

CompletedPhase 4Results postedNCT00701363

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

Ipsenn = 124Oct 2008 to May 2013

Acromegaly

Trial page ClinicalTrials.govUpdated 29 Jan 2019

CompletedPhase 4NCT00627796

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

Federico II Universityn = 27Jan 2003 to Dec 2007

Acromegaly

Trial page ClinicalTrials.govUpdated 3 Mar 2008

Status unknownPhase 4NCT00543179

Treatment of the Dumping Syndrome With Lanreotide Autogel®

Radboud University Medical CenterStart Oct 2007

Dumping Syndrome

Trial page ClinicalTrials.govUpdated 12 Oct 2007

CompletedPhase 4NCT00145405

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

Odense University Hospitaln = 12Sept 2002 to Dec 2004

Acromegaly

Trial page ClinicalTrials.govUpdated 8 Sept 2006

Active, not recruitingPhase 3NCT05477576

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

RayzeBio, Inc.n = 34324 Mar 2022 to est. Dec 2030

GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor Disease · Neuroendocrine Tumors · Carcinoid · Carcinoid Tumor · Pancreatic NET

Trial page ClinicalTrials.govUpdated 5 Oct 2026

RecruitingPhase 3NCT06878664

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Grupo Espanol de Tumores Neuroendocrinosn = 16612 Jun 2025 to est. Jan 2029

Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

Trial page ClinicalTrials.govUpdated 16 Sept 2026

Active, not recruitingPhase 3NCT05050942

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Camurus ABn = 33222 Oct 2021 to est. Nov 2028

Gastro-enteropancreatic Neuroendocrine Tumor

Trial page ClinicalTrials.govUpdated 28 Jul 2026

CompletedPhase 3NCT02127437

Lanreotide In Polycystic Kidney Disease Study

Assistance Publique - Hôpitaux de Parisn = 15919 Sept 2014 to 31 Jul 2019

Autosomal Dominant Polycystic Kidney Disease (ADPKD

Trial page ClinicalTrials.govUpdated 8 Apr 2026

RecruitingPhase 3NCT06807437

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Networkn = 2749 May 2025 to est. 1 Nov 2027

Pancreatic Carcinoma · Pancreatic Neoplasm

Trial page ClinicalTrials.govUpdated 31 Mar 2026

CompletedPhase 3Results postedNCT00353496

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Ipsenn = 264Jun 2006 to Apr 2013

Endocrine Tumors

Trial page ClinicalTrials.govUpdated 5 Mar 2025

CompletedPhase 3Results postedNCT04852679

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Ipsenn = 4324 May 2021 to 13 Jan 2023

Gastroenteropancreatic Neuroendocrine Tumor

Trial page ClinicalTrials.govUpdated 1 Oct 2024

TerminatedPhase 2/3Results postedNCT02288377

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

Federation Francophone de Cancerologie Digestiven = 53Jan 2015 to Jan 2020

Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours

Trial page ClinicalTrials.govUpdated 18 Jan 2023

CompletedPhase 3Results postedNCT00690898

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

Ipsenn = 108May 2008 to Feb 2012

Acromegaly

Trial page ClinicalTrials.govUpdated 14 Oct 2022

CompletedPhase 3Results postedNCT00774930

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Ipsenn = 115May 2009 to Dec 2015

Carcinoid Syndrome

Trial page ClinicalTrials.govUpdated 14 Oct 2022

CompletedPhase 3Results postedNCT00842348

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

Ipsenn = 89Feb 2009 to Dec 2015

Non Functioning Entero-pancreatic Endocrine Tumour

Trial page ClinicalTrials.govUpdated 12 Oct 2022

CompletedPhase 3Results postedNCT00383708

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Ipsenn = 125Oct 2006 to Oct 2008

Acromegaly

Trial page ClinicalTrials.govUpdated 27 Sept 2022

25 more mention it but do not test it. They are not trials of Lanreotide: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

908 studies match. Retracted studies are left out.

Showing 22 of 908 studiesquery qry_9f8caf433114d98ef621dfcd

Studies with results

110 studies in all, 8 on this page

Randomized controlled trial · 2014

6 results

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Caplin et al. 2014The New England journal of medicinen = 204cited by 1,288

PMID 25014687DOI 10.1056/nejmoa1316158PUB-25014687

Rights unknown6 results where Lanreotide was given

Source link See results (6)

Non-randomized trial · 2003

3 results

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Faiss et al. 2003Journal of clinical oncology : official journal of the American Society of Clinical Oncologyn = 25cited by 309

PMID 12860945DOI 10.1200/jco.2003.12.142PUB-12860945

Full text at the publisher3 results where Lanreotide was given

Publisher page See results (3)

In vitro (cells) · 1997

1 result

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Shimon et al. 1997The Journal of clinical investigationcited by 195

PMID 9045884PMC507864DOI 10.1172/jci119225PUB-09045884

Rights unknown1 result where Lanreotide was given

Source link See results (1)

Randomized controlled trial · 2009

4 results

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

van Keimpema et al. 2009Gastroenterologyn = 54cited by 176

PMID 19646443DOI 10.1053/j.gastro.2009.07.052PUB-19646443

Full text at the publisher4 results where Lanreotide was given

Publisher page See results (4)

Non-randomized trial · 2016

8 results

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

Caplin et al. 2016Endocrine-related cancern = 101cited by 176

PMID 26743120PMC4740728DOI 10.1530/erc-15-0490PUB-26743120

CC BY8 results where Lanreotide was given

Download PDF See results (8)

Non-randomized trial · 2000

13 results

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

O'Toole et al. 2000Cancern = 33cited by 173

PMID 10679645DOI 10.1002/(sici)1097-0142(20000215)88:4<770::aid-cncr6>3.0.co;2-0PUB-10679645

Full text at the publisher7 results where Lanreotide was given

Publisher page See results (13)

In vitro (cells) · 1997

1 result

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Shimon et al. 1997The Journal of clinical investigationcited by 156

PMID 9410919PMC508437DOI 10.1172/jci119779PUB-09410919

Rights unknown1 result where Lanreotide was given

Source link See results (1)

Non-randomized trial · 2000

4 results

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.

Ducreux et al. 2000The American journal of gastroenterologyn = 39cited by 134

PMID 11095353DOI 10.1111/j.1572-0241.2000.03210.xPUB-11095353

Full text at the publisher4 results where Lanreotide was given

Publisher page See results (4)

More studies

777 studies in all, 14 on this page

PubMed tag: none · 2000

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.

Reubi et al. 2000European journal of nuclear medicinecited by 746

PMID 10774879DOI 10.1007/s002590050034PUB-10774879

Full text at the publisher

Publisher page

Indexing hint: In vitro study · 2001

Corrected

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.

Reubi et al. 2001European journal of nuclear medicinecited by 444

PMID 11504080DOI 10.1007/s002590100541PUB-11504080

Full text at the publisher

Publisher page Read the notice

PubMed tag: Meta-Analysis, Comparative Study · 2005

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Freda et al. 2005The Journal of clinical endocrinology and metabolismcited by 220

PMID 15886238DOI 10.1210/jc.2005-0260PUB-15886238

Full text at the publisher

Publisher page

PubMed tag: Comparative Study, Evaluation Study · 2003

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Wild et al. 2003European journal of nuclear medicine and molecular imagingcited by 199

PMID 12937948DOI 10.1007/s00259-003-1255-5PUB-12937948

Rights unknown

Source link

PubMed tag: none · 2003

Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension.

Valéry et al. 2003Proceedings of the National Academy of Sciences of the United States of Americacited by 182

PMID 12930900PMC193548DOI 10.1073/pnas.1730609100PUB-12930900

Rights unknown

Source link

PubMed tag: none · 2001

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.

Aparicio et al. 2001European journal of cancer (Oxford, England : 1990)cited by 147

PMID 11334727DOI 10.1016/s0959-8049(01)00073-9PUB-11334727

Full text at the publisher

Publisher page

PubMed tag: Clinical Trial, Phase II, Clinical Trial · 2002

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.

Virgolini et al. 2002Seminars in nuclear medicinecited by 144

PMID 11965610DOI 10.1053/snuc.2002.31565PUB-11965610

Full text at the publisher

Publisher page

PubMed tag: none · 2021

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis.

Ito et al. 2021Journal of gastroenterologycited by 140

PMID 34586495PMC8531106DOI 10.1007/s00535-021-01827-7PUB-34586495

CC BY

Download PDF

PubMed tag: none · 2005

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Melmed et al. 2005The Journal of clinical endocrinology and metabolismcited by 134

PMID 15827109DOI 10.1210/jc.2004-2466PUB-15827109

Rights unknown

Source link

PubMed tag: Meta-Analysis · 2014

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

Carmichael et al. 2014The Journal of clinical endocrinology and metabolismcited by 132

PMID 24606084PMC4010703DOI 10.1210/jc.2013-3757PUB-24606084

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Clinical Trial, Phase II, Clinical Trial · 1999

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

Wymenga et al. 1999Journal of clinical oncology : official journal of the American Society of Clinical Oncologycited by 131

PMID 10561168DOI 10.1200/jco.1999.17.4.1111PUB-10561168

Full text at the publisher

Publisher page

PubMed tag: Multicenter Study · 2006

Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

Colao et al. 2006The Journal of clinical endocrinology and metabolismcited by 131

PMID 16263832DOI 10.1210/jc.2005-1208PUB-16263832

Rights unknown

Source link

PubMed tag: Clinical Trial, Phase III, Multicenter Study · 2014

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Caron et al. 2014The Journal of clinical endocrinology and metabolismcited by 129

PMID 24423301PMC4009579DOI 10.1210/jc.2013-3318PUB-24423301

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Clinical Trial, Comparative Study · 2002

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.

Caron et al. 2002The Journal of clinical endocrinology and metabolismcited by 126

PMID 11788630DOI 10.1210/jcem.87.1.8153PUB-11788630

Full text at the publisher

Publisher page

No result for Lanreotide (3 studies on this page, 21 in all)

These studies name Lanreotide but give no result for it (for example, the results concern another peptide in the study).

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase III · 2014

10 results

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Gadelha et al. 2014The lancet. Diabetes & endocrinologycited by 278

PMID 25260838DOI 10.1016/s2213-8587(14)70169-xPUB-25260838

Full text at the publisher10 results

Publisher page See results (10)

PubMed tag: Randomized Controlled Trial, Clinical Trial, Phase II · 2010

4 results

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn et al. 2010The Journal of clinical endocrinology and metabolismcited by 138

PMID 20410233DOI 10.1210/jc.2009-2272PUB-20410233

Rights unknown4 results

Source link See results (4)

Indexing hint: In vitro study · 2009

12 results

Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.

Lesche et al. 2009The Journal of clinical endocrinology and metabolismcited by 125

PMID 19001514DOI 10.1210/jc.2008-1919PUB-19001514

Full text at the publisher12 results

Publisher page See results (12)

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Lanreotide studies: 110 papers with results

Page 1 of 3

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Meijer E · JAMA · 2018
Randomized controlled trial · 10 results
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME · The New England journal of medicine · 2014
Randomized controlled trial · 6 results
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM · Gastroenterology · 2019
Randomized controlled trial · 4 results
Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial.
Gauthier T · European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2012
Randomized controlled trial · 3 results
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.
Joly D · Kidney international · 2026
Randomized controlled trial · 8 results
Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
An Z · BMC endocrine disorders · 2020
Randomized controlled trial · 7 results
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2016
Randomized controlled trial · 3 results
Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae.
Gayral F · Annals of surgery · 2009
Randomized controlled trial · 4 results
Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
Mao ZG · European journal of endocrinology · 2010
Randomized controlled trial · 3 results
Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
Mariani P · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
Randomized controlled trial · 6 results
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
Santo A · Lung cancer (Amsterdam, Netherlands) · 2019
Randomized controlled trial · 6 results
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA Jr · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2018
Randomized controlled trial · 5 results
Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.
Chang TC · Journal of endocrinological investigation · 2006
Randomized controlled trial · 6 results
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
van Keimpema L · Gastroenterology · 2009
Randomized controlled trial · 4 results
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Lepage C · European journal of cancer (Oxford, England : 1990) · 2022
Randomized controlled trial · 3 results
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.
Raj N · JCO oncology practice · 2022
Randomized controlled trial · 3 results
Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment.
Boertien TM · The Lancet regional health. Europe · 2024
Randomized controlled trial · 5 results
Clinical trial: The effectiveness of long-acting somatostatin analogue for output reduction of high-output intestinal fistula or small bowel enterostomy. A randomised controlled trial.
Timmer AS · Alimentary pharmacology & therapeutics · 2024
Randomized controlled trial · 2 results
Efficacy and safety of lanreotide in postoperative dumping syndrome: A Phase II randomised and placebo-controlled study.
Wauters L · United European gastroenterology journal · 2019
Randomized controlled trial · 7 results
Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
Lantinga MA · Drug safety · 2017
Randomized controlled trial · 2 results
Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation.
Aapkes SE · Drugs in R&D · 2021
Randomized controlled trial · 5 results
Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N · The AAPS journal · 2016
Randomized controlled trial · 4 results
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA Jr · The oncologist · 2018
Randomized controlled trial · 6 results
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
Melmed S · Pituitary · 2010
Randomized controlled trial · 11 results
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.
Baudin E · Endocrine-related cancer · 2024
Randomized controlled trial · 8 results
Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
Li ZQ · The Journal of international medical research · 2012
Randomized controlled trial · 4 results
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E · Cancer · 2006
Randomized controlled trial · 3 results
Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.
Trocóniz IF · Clinical pharmacokinetics · 2009
Randomized controlled trial · 9 results
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A · The Journal of clinical endocrinology and metabolism · 2017
Randomized controlled trial · 10 results
Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
Schiedermaier P · Alimentary pharmacology & therapeutics · 2003
Randomized controlled trial · 3 results
Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G · Clinical endocrinology · 2002
Randomized controlled trial · 6 results
Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.
Bronstein M · Clinical endocrinology · 2005
Randomized controlled trial · 9 results
Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion.
Sieber CC · Clinical pharmacology and therapeutics · 2004
Randomized controlled trial · 6 results
A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
Andries M · Clinical endocrinology · 2008
Randomized controlled trial · 19 results
Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study.
Mottet C · Hepatology (Baltimore, Md.) · 1998
Randomized controlled trial · 5 results
Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans.
Lamrani A · British journal of clinical pharmacology · 1997
Randomized controlled trial · 7 results
Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study.
Falconi M · Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2002
Randomized controlled trial · 6 results
Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
Gancel A · Clinical endocrinology · 1994
Randomized controlled trial · 14 results
Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C · BMC cancer · 2019
Randomized controlled trial · 2 results
Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.
Dromain C · The oncologist · 2021
Randomized controlled trial · 3 results
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M · The oncologist · 2024
Randomized controlled trial · 1 result
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M · European journal of cancer (Oxford, England : 1990) · 2021
Non-randomized trial · 7 results
A phase II trial of lanreotide for the prevention of postoperative pancreatic fistula.
Pillarisetty VG · HPB : the official journal of the International Hepato Pancreato Biliary Association · 2022
Non-randomized trial · 5 results
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
Chanson P · Clinical endocrinology · 2008
Non-randomized trial · 7 results
Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study.
Duck L · Clinical therapeutics · 2021
Non-randomized trial · 4 results
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.
Lombardi G · Journal of endocrinological investigation · 2009
Non-randomized trial · 22 results
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
Charles J · Cancer medicine · 2026
Non-randomized trial · 7 results
Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
Ito T · Investigational new drugs · 2017
Non-randomized trial · 7 results
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M · BMC cancer · 2013
Non-randomized trial · 8 results
Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.
Bevan JS · Clinical endocrinology · 2008
Non-randomized trial · 6 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Somatuline Depot	27 Oct 2026	dailymed.nlm.nih.gov (opens in a new tab)
EU	EMA	Lanreotide	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Not listed as banned by WADA The substance is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

98 safety results for Lanreotide.

Human evidence· 98

In ADPKD patients, seven lanreotide recipients developed eight hepatic cyst infections during 342 patient-years (0.23 cases per 10 patient-years), exclusively with lanreotide (p<0.001).
Randomized controlled trialn = 309
Patients with hepatic cyst infection
7 patients
lanreotide use
Hepatic cyst infection episodes
8 episodes
lanreotide use
Exposure to lanreotide
342 patient-years
lanreotide use
2 more measurements in the study.
In polycystic kidney disease, gallstones formed in 19/124 lanreotide patients (15%) versus 1/125 standard-care patients (1%), with odds ratio 25.9.
Randomized controlled trialn = 249
Patients with new gallstones
19 patients
lanreotide, of 124 patients
Patients with new gallstones
15%
lanreotide
Patients with new gallstones
1 patients
standard of care, of 125 patients
4 more measurements in the study.
In patients with enteropancreatic NETs, treatment-related diarrhea occurred in 26% with lanreotide versus 9% with placebo.
Randomized controlled trialn = 204
Treatment-related diarrhea
26%
lanreotide
Treatment-related diarrhea
9%
placebo
In adults with ADPKD, gastrointestinal adverse events were more frequent with lanreotide than placebo.
Randomized controlled trialn = 144
In Chinese patients with acromegaly, safety profiles were similar with autogel and prolonged-release lanreotide.
Randomized controlled trialn = 128
In acromegaly with macroadenomas, surgical morbidity was similar after lanreotide pretreatment and direct surgery: 14.3% versus 10.2%, P=0.538.
Randomized controlled trialn = 98
Surgical morbidity
12 patients
both groups
Surgical morbidity
12.2%
both groups
Surgical morbidity
14.3%
lanreotide pretreatment
1 more measurement in the study.
In NET patients, mean injection pain over the first three injections was 2.4 ± 1.9 with octLAR versus 1.9 ± 1.5 with lanreotide (P = .5).
Randomized controlled trialn = 51
Mean injection site pain score
2.4 0-10 scale
first value of reported pair, octLAR
SD of injection site pain score
1.9 0-10 scale
first value of reported pair, octLAR
Mean injection site pain score
1.9 0-10 scale
second value of reported pair, lanreotide
2 more measurements in the study.
In neuroendocrine tumor patients, lanreotide Autogel and microparticles were well tolerated, with no safety concerns identified.
Randomized controlled trialn = 46

The top 24 of 98 results.

Doses studied · 104

The doses that these studies used. They are not recommendations.

120 mg every 4 weeksHuman
Species
human
Route
subcutaneous
Duration
2.5 years
Design
Randomized controlled trial · n = 309
120 mg every 28 daysHuman
Species
human
Route
Not reported
Duration
96 weeks
Design
Randomized controlled trial · n = 204
120 mg every 4 weeksHuman
Species
human
Route
subcutaneous
Duration
120 weeks
Design
Randomized controlled trial · n = 175
90 mgHuman
Species
human
Route
Not reported
Duration
Not reported
Design
Randomized controlled trial · n = 145
120 mg monthlyHuman
Species
human
Route
injection
Duration
three years
Design
Randomized controlled trial · n = 144
Autogel 60/90/120 mg monthlyHuman
Species
human
Route
deep subcutaneous injection
Duration
32 weeks
Design
Randomized controlled trial · n = 128

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
120 mg every 4 weeks	Human	human	subcutaneous	2.5 years	Randomized controlled trial · n = 309
120 mg every 28 days	Human	human	Not reported	96 weeks	Randomized controlled trial · n = 204
120 mg every 4 weeks	Human	human	subcutaneous	120 weeks	Randomized controlled trial · n = 175
90 mg	Human	human	Not reported	Not reported	Randomized controlled trial · n = 145
120 mg monthly	Human	human	injection	three years	Randomized controlled trial · n = 144
Autogel 60/90/120 mg monthly	Human	human	deep subcutaneous injection	32 weeks	Randomized controlled trial · n = 128

6 of 104 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000142
Peptide version: 2
Peptide hash: 11b39a912f1e8bfb…
Data version: 308560

Latest changes

28 Oct 2026UpdatedData version 304189
27 Oct 2026CreatedData version 256714

For developers

curl -s https://pepbank.io/v1/briefs/lanreotide

Evidence summary for Lanreotide: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Growth hormone and IGF-1Endocrine and hormones	Human: 109 results from 21 studies: 10 increase, 38 decrease, 11 no significant change, 50 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	Lab: 8 results from 5 studies: 7 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	118
Tumor growthGastrointestinal	Human: 88 results from 36 studies: 11 increase, 11 decrease, 15 no significant change, 51 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 2 studies: 1 decrease, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 16 results from 9 studies: 2 increase, 10 decrease, 2 no significant change, 2 not reported. Strongest design: Ex vivo tissue	No results	106
Adverse eventsWhole body	Human: 68 results from 36 studies: 10 increase, 6 decrease, 3 no significant change, 49 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	68
Gastrointestinal protectionGastrointestinal	Human: 35 results from 9 studies: 9 increase, 18 decrease, 7 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	35
PharmacokineticsPharmacology	Human: 29 results from 9 studies: 7 increase, 1 decrease, 4 no significant change, 17 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	29
Gastrointestinal adverse eventsGastrointestinal	Human: 26 results from 18 studies: 6 increase, 1 decrease, 1 no significant change, 18 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	26
Glycemic controlMetabolic and weight	Human: 16 results from 2 studies: 2 decrease, 10 no significant change, 1 mixed, 3 not reported. Strongest design: Non-randomized trial	No results	No results	No results	16
MortalityWhole body	Human: 13 results from 10 studies: 4 increase, 2 no significant change, 7 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Liver fat and liver functionLiver	Human: 12 results from 4 studies: 1 increase, 8 decrease, 1 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Thyroid functionEndocrine and hormones	Human: 12 results from 3 studies: 6 decrease, 6 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Cancer biomarkers and prognosisGastrointestinal	Human: 11 results from 3 studies: 8 decrease, 1 no significant change, 2 not reported. Strongest design: Non-randomized trial	No results	No results	No results	11
Quality of lifeWhole body	Human: 11 results from 11 studies: 2 increase, 1 decrease, 5 no significant change, 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	11

Outcome group	Human	Animal	Lab	Computer model	Total
Growth hormone and IGF-1Endocrine and hormones	Human: 109 results from 21 studies: 10 increase, 38 decrease, 11 no significant change, 50 not reported. Strongest design: Randomized controlled trial	Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo)	Lab: 8 results from 5 studies: 7 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	118
Tumor growthGastrointestinal	Human: 88 results from 36 studies: 11 increase, 11 decrease, 15 no significant change, 51 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 2 studies: 1 decrease, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 16 results from 9 studies: 2 increase, 10 decrease, 2 no significant change, 2 not reported. Strongest design: Ex vivo tissue	No results	106
Adverse eventsWhole body	Human: 68 results from 36 studies: 10 increase, 6 decrease, 3 no significant change, 49 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	68
Gastrointestinal protectionGastrointestinal	Human: 35 results from 9 studies: 9 increase, 18 decrease, 7 no significant change, 1 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	35
PharmacokineticsPharmacology	Human: 29 results from 9 studies: 7 increase, 1 decrease, 4 no significant change, 17 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	29
Gastrointestinal adverse eventsGastrointestinal	Human: 26 results from 18 studies: 6 increase, 1 decrease, 1 no significant change, 18 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	26
Glycemic controlMetabolic and weight	Human: 16 results from 2 studies: 2 decrease, 10 no significant change, 1 mixed, 3 not reported. Strongest design: Non-randomized trial	No results	No results	No results	16
MortalityWhole body	Human: 13 results from 10 studies: 4 increase, 2 no significant change, 7 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Liver fat and liver functionLiver	Human: 12 results from 4 studies: 1 increase, 8 decrease, 1 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Thyroid functionEndocrine and hormones	Human: 12 results from 3 studies: 6 decrease, 6 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	12
Cancer biomarkers and prognosisGastrointestinal	Human: 11 results from 3 studies: 8 decrease, 1 no significant change, 2 not reported. Strongest design: Non-randomized trial	No results	No results	No results	11
Quality of lifeWhole body	Human: 11 results from 11 studies: 2 increase, 1 decrease, 5 no significant change, 3 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	11